PT  - JOURNAL ARTICLE
AU  - Rossetto, Federica
AU  - Borgnis, Francesca
AU  - Blasi, Valeria
AU  - Banfi, Paolo Innocente
AU  - Tavanelli, Monica
AU  - Realdon, Olivia
AU  - Mantovani, Fabrizia
AU  - Foglia, Emanuela
AU  - Garagiola, Elisabetta
AU  - Croce, Davide
AU  - Nalin, Marco
AU  - Baglio, Francesca
TI  - System Integrated Digital Empowerment and Rehabilitation to promote patient Activation and well-Being (SIDERA^B): Protocol for a Randomized Crossover Trial on Effectiveness and Implementation
AID  - 10.1101/2022.04.19.22274012
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.19.22274012
4099  - http://medrxiv.org/content/early/2022/04/19/2022.04.19.22274012.short
4100  - http://medrxiv.org/content/early/2022/04/19/2022.04.19.22274012.full
AB  - CONTEXT the current increasing demand for rehabilitation among people with Non-Communicable Diseases (NCDs) requires the identification of home-based digital solutions alternative to conventional in-clinic interventions.OBJECTIVE this protocol proposes to test the effectiveness of an individualized telerehabilitation platform (SIDERA^B), with respect to the traditional face-to-face rehabilitation, in ensuring the continuity of care in patients with NCDs.DESIGN, SETTING, AND SUBJECTS this randomized, single-blind, controlled two-period crossover trial will involve about 150 outpatients with NCDs (N=40 with Chronic Heart Failure – CHF, N=60 with Chronic Obstructive Pulmonary Disease – COPD, and N=50 with Parkinson’s Disease – PD) from the rehabilitation units of IRCCS Fondazione Don Carlo Gnocchi of Milan. Each participant will experience, consequently, two different types of interventions: rehabilitation with the SIDERA^B system (SIDERA^B – S), which allow for both tele-rehabilitation activities and tele-monitoring of vital parameters, and rehabilitation as usual (Usual Care – U) including a manual of rehabilitative exercises and self-monitoring of vital parameters.INTERVENTIONS subjects will be randomly assigned to one of the two specified sequences of interventions: U/S/U (the USU group), and S/U (the SU group). Both groups will be assessed at the baseline (T1), after the first intervention (T2), and after the second intervention (T3), with a follow-up evaluation (T4) scheduled only for the USU group.MAIN OUTCOME MEASURES a multifaceted evaluation including quality of life and clinical/functional measures will be conducted at each time-point of assessment. The primary outcome measures will be 1) change in activation of patients measured by the Patient Activation Measure scale, and 2) change in subject’s level of activity and participation measured by the WHO Disability Assessment Schedule 2.0.CONCLUSION SIDERA^B could represent a promising innovative digital solution able to support the ongoing migration of rehabilitation care from the clinic to the patient’s home, for the optimal long-term management of NCDs.Trial registration The SIDERA^B trial was registered in the clinicaltrials.gov database (identifier NCT04041193) on August 1, 2019.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04041193Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04041193 Funding StatementThis study is supported by Lombardy Region (Announcement POR-FESR 2014 2020 Azione I.1.B.1.3), within the project named SIDERA^B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Ethical Committee of IRCCS Don Carlo Gnocchi Foundation gave approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://clinicaltrials.gov/ct2/show/NCT04041193